In Treatment of Resistant Tuberculosis (TB) In multidrug-resistant (MDR) tuberculosis, the causative bacteria produce an enzyme called beta-lactamase. This enzyme breaks down the antibiotics and makes them ineffective. As a result, the bacteria become resistant to the antibiotic being used for treatment. Jomoxlin Clav Dry Syrup comprises two active ingredients, amoxycillin and clavulanic acid. While clavulanic acid stops the enzyme from rendering amoxycillin ineffective, amoxycillin works towards killing the tuberculosis-causing bacteria. This makes the combination of amoxycillin and clavulanic acid an effective treatment for resistant tuberculosis. In Treatment of Bacterial infections Jomoxlin Clav Dry Syrup contains two different medicines, Amoxycillin and Clavulanic Acid, that work together to kill the bacteria that cause infections. Amoxycillin works by stopping the growth of bacteria. Clavulanic Acid reduces resistance and enhances the activity of Amoxycillin against bacteria. This combination medicine can be used to treat many different bacterial infections such as ear, sinus, throat, lung, urinary tract, skin, teeth, joints, and bones. It usually makes you feel better within a few days, but you should continue taking it as prescribed even when you feel better to make sure that all bacteria are killed and do not become resistant.
Jomoxlin Clav Dry Syrup should be used with caution in patients with kidney disease. Dose adjustment of Jomoxlin Clav Dry Syrup may be needed. Please consult your doctor.
Jomoxlin Clav Dry Syrup should be used with caution in patients with liver disease. Dose adjustment of Jomoxlin Clav Dry Syrup may be needed. Please consult your doctor. Consult with your child’s doctor before giving Jomoxlin Clav Dry Syrup to your child in case of a severe form of liver disease.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More
Marketer/Manufacturer: Cipla Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Chemross Lifesciences || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Cian Health Care Pvt Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Remandish Pharma Pvt Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Jagsonpal Pharmaceuticals Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Pidolma Healthcare Pvt Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Horean Healthcare Private Limited || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Akumentis Healthcare Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Gurnex Biotech || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Anvicure Drugs || ₹14.5/tablet (25% cheaper)